13-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine has been studied in 6 papers since 2024: 1 trial and 5 observational studies in people; 2 in the past year. The newest paper, Mar 30, 2026: “Effectiveness of influenza and pneumococcal vaccination in frail older adults”.
6 papers study it6 findingsUpdated
“While PCV13 alone also reduced the risk of pneumonia hospitalization (adjusted hazard ratio, 0.96 [95% CI, .92-.99])”
None of its findings points the other way.
- 2 independent labs in 2 countries
- 1 trial, none about aging
- Funders: Ministrstvo za zdravje and 3 more
- 1 of 1 trial sponsored by its developers
- Human trial1
- Humans5
What did studies of 13-valent pneumococcal conjugate vaccine find?
4Studies of 13-valent pneumococcal conjugate vaccine measured 4 outcomes; the most studied are mortality (1 study), lifespan (1) and hospitalizations (1).
Mortality
downin humans1
1 study
Mortality
downin humans1
13-valent pneumococcal conjugate vaccine is linked with lower mortality in humans (0.86 [95% confidence interval, .83-.89]).
“and all-cause mortality (0.86 [95% confidence interval, .83-.89])”
Humans
Real-World Effectiveness of Sequential Pneumococcal Vaccination in Older Adults: A Cohort Study
The Journal of infectious diseases
Lifespan
upin humans1
1 study
Lifespan
upin humans1
13-valent pneumococcal conjugate vaccine is linked with longer lifespan in patients with COPD and/or stable angina.
“Survival was higher in both vaccinated groups over 10 years.”
Humansin patients with COPD and/or stable angina10 yearsmales
Vaccines
Hospitalizations
downin humans1
1 study
Hospitalizations
downin humans1
13-valent pneumococcal conjugate vaccine is linked with lower hospitalizations in patients with COPD and/or stable angina.
“vaccinated groups consistently showed lower rates than the unvaccinated group.”
Humansin patients with COPD and/or stable angina10 yearsmales
Vaccines
COPD exacerbations
downin humans1
1 study
COPD exacerbations
downin humans1
13-valent pneumococcal conjugate vaccine is linked with lower COPD exacerbations in patients with COPD and/or stable angina.
“vaccinated groups consistently showed lower rates than the unvaccinated group.”
Humansin patients with COPD and/or stable angina10 yearsmales
Vaccines
What is 13-valent pneumococcal conjugate vaccine linked with?
2Studies link 13-valent pneumococcal conjugate vaccine with 2 measures, most often pneumonia (1 study) and community-acquired pneumonia (1).
Pneumonia
downin humans1
1 study
Pneumonia
downin humans1
13-valent pneumococcal conjugate vaccine is linked with a lower risk of pneumonia in humans (adjusted hazard ratio, 0.96 [95% CI, .92-.99]).
“While PCV13 alone also reduced the risk of pneumonia hospitalization (adjusted hazard ratio, 0.96 [95% CI, .92-.99])”
Humans
Real-World Effectiveness of Sequential Pneumococcal Vaccination in Older Adults: A Cohort Study
The Journal of infectious diseases
Community-acquired pneumonia
downin humans1
1 study
Community-acquired pneumonia
downin humans1
13-valent pneumococcal conjugate vaccine is linked with a lower risk of community-acquired pneumonia in patients with COPD alone.
“PCV13 significantly reduced CAP in patients with COPD alone but not in those with comorbid angina.”
Humansin patients with COPD alone10-yearmales
Vaccines
Trial sponsors
Company1 trialPhase 4908 people